Citations

Clear

5 citation(s) found for "McGuire, Amy L".

Elective genomic sequencing for adults in research, clinical and commercial contexts
Linderman, Michael D. , Adelson, Sophia , Berro, Tala , Crawford, Scott , Cunningham, Tshaka J., Esplin, Edward D. , Ewing-Crawford, Altovise T, Nielsen, Daiva E. , Andrighetti, Heather, Bleyl, Steven B., Haverfield, Eden , Hegde, Madhuri , Konstantinos, Lazaridis N, Leonard, Debra G. B. , May, Thomas , McGinniss, Molly, Pandya, Vaibhav, Schadt, Eric E. , Zettler, Bethany , Team, PeopleSeq Study, Adelson, Sophia M , Berro, Tala M , Crawford, Scott D , Esplin, Edward D , Nielsen, Daiva E , Pereira, Stacey , Schmidlen, Tara , Haverfield, Eden V , Hegde, Madhuri , Kruszka, Paul , Leonard, Debra , May, Thomas , Schadt, Eric E , Tzovaras, Bastian Greshake , Zettler, Bethany , McGuire, Amy L , Green, Robert C. , Berro, Tala M., Anderson, Jennifer L., Cunningham, Tshaka, Ewing, Altovise T. , Nielsen, Daiva E., Church, George M. , Konstantinos, Lazaridis N., McGinniss, Molly A. , Schadt, Eric E., Green, Robert C., Juusola, Jane , McWalter, Kirsty , Esplin, Ed, Haverfield, Eden, Hazell, Allison, Gu, Jessica, Hogan, Jennifer, Church, George , Ball, Mad Price , McGinnis, Molly, Schadt, Eric, Linderman, Michael, McGuire, Amy, Christensen, Kurt D. , Caskey, Thomas, Zoltick, Emilie S. , Crawford, Scott, Young, Robert, Hunsanger, Jillian, Bradley, Sophia, Cunningham, Tshaka, Roberts, Scott, Ricks‐Santi, Luisel , Lillard, James, Washington, Kareem N., Johnson, Anthony

Mayo Clinic

No container title available | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.09.26355296 | PMID 42369514 Get It

Abstract Purpose Elective genomic sequencing (EGS) returns monogenic disease findings in multiple genes, including potentially novel variants, and may also provide participants with carrier status, pharmacogenomic and other health-related information. The PeopleSeq Study assessed participants’ motivations for and concerns about EGS and the associated clinical and psychosocial outcomes across diverse EGS providers. Methods We administered a shared questionnaire to participants who chose to undergo EGS via 18 academic, clinical, or commercial EGS platforms. Results We enrolled 1575 participants, of whom 1147 (72.8%) completed a questionnaire after receiving their EGS results. A majority (60.3%) of the participants who completed a post-result questionnaire self-reported receiving results they assessed as important, including negative findings, and 75.9% reported a form of health-related utility. Among a subset (19.4%) who shared their EGS reports, 16.6% (37 of n =223) received a monogenic finding and self-reported results deemed “important” were consistent with EGS reports. Most participants (74.1%) discussed their results with their family, but fewer discussed their results with a healthcare provider other than the site team (41.7%) or had one or more medical visits as a direct result of their EGS testing (23.1%). Participants expressed diverse motivations for EGS, with 91.4% expressing interest in their personal disease risk and 54% who expressed quasi-indication-based motivations related to family medical history. Individuals motivated by family history reported important results at a significantly higher rate. Conclusions Early adopters of EGS are motivated by general interest in their health as well as quasi-indication-based considerations such as family history. A majority of participants learned results they considered medically important, but a much smaller segment engaged healthcare providers with their results.
Treatment Decision‐Making Roles and Preferences Among Adolescents and Young Adults With Cancer
Gutierrez, Amanda M. , Robinson, Jill O. , Allen‐Rhoades, Wendy , Canfield, Isabel, Hsu, Rebecca , Scollon, Sarah R., Desrosiers‐Battu, Lauren R., Schneider, Nicole M. , Lin, Frank Y. , Parsons, D. Williams , Majumder, Mary A. , Malek, Janet , McGuire, Amy L., Desrosiers, Lauren , Canfield, Isabel , Scollon, Sarah , Allen-Rhoades, Wendy A , Smith, Hadley S , Canfield, Isabel , Hsu, Rebecca L , Scollon, Sarah R , Desrosiers-Battu, Lauren R , Lin, Frank Y , Parsons, D Williams , Plon, Sharon E. , McGuire, Amy L

Mayo Clinic

Pediatric Blood & Cancer | March 19, 2026 | Volume: 73 | Issue: 6 | Pages: No page available

10.1002/1545-5017.70235 | PMID 41852319 Get It

ABSTRACT Background Decision‐making (DM) dynamics between adolescents and young adults (AYAs) with cancer, parents, and oncologists remain underexplored in diverse populations. We examined cancer treatment DM preferences among an ethnically and socioeconomically diverse group of AYAs and their parents. Procedure We surveyed AYAs with cancer ( n = 75) and their parents ( n = 52) participating in the Texas KidsCanSeq study. Among AYA‐parent pairs, we compared preferred and actual treatment DM roles. We explored associations among DM roles, having pediatric‐to‐adult care transition discussions, and clinical and sociodemographic characteristics. We report AYAs’ and parents’ preferences for involvement in shared decision‐making (SDM) with oncologists about cancer treatment. Results AYAs’ DM role preferences varied: 44% preferred to equally share DM with parents, 31% preferred AYA‐led DM, and 25% preferred parent‐led DM. Parents who preferred parent‐led DM had younger AYAs than parents who preferred equally shared DM ( p = 0.011). For actual DM, 48% of AYAs reported DM was equally shared, 24% reported DM was AYA‐led, and 28% reported DM was parent‐led. Most AYAs had their preferred role (73%). AYAs’ actual role did not significantly differ from their own or their parents’ preferences (both p > 0.05). Approximately half of AYAs reported recent pediatric‐to‐adult care transition discussions. AYAs’ DM preferences and participation in transition discussions did not significantly differ along clinical or sociodemographic characteristics (all p > 0.05). AYAs and parents perceived high importance across all aspects of SDM with oncologists. Conclusion In this diverse study population, AYAs desired engagement in treatment DM and SDM. Although specific role preferences varied, opportunities existed to increase discussion around pediatric‐to‐adult care transition.
Views of Adolescents and Young Adults with Cancer and Their Oncologists Toward Patients' Participation in Genomic Research
Gutierrez, Amanda M. , Robinson, Jill O. , Raesz-Martinez, Robin, Canfield, Isabel , Majumder, Mary A. , Scollon, Sarah , Desrosiers, Lauren , Hsu, Rebecca , Allen‐Rhoades, Wendy , Parsons, D. Williams , Malek, Janet , Hsu, Rebecca L , Parsons, D Williams , Allen-Rhoades, Wendy A , Scollon, Sarah R , Desrosiers-Battu, Lauren R , Plon, Sharon E. , McGuire, Amy L

Mayo Clinic

Journal of Adolescent and Young Adult Oncology | January 3, 2023 | Volume: 12 | Issue: 5 | Pages: 773-781

10.1089/jayao.2022.0066 | PMID 36595372 Get It

Consumer Perspectives on Access to Direct‐to‐Consumer Genetic Testing: Role of Demographic Factors and the Testing Experience
Gollust, Sarah E. , Gray, Stacy W. , Carere, Deanna Alexis , Koenig, Barbara A. , McGuire, Amy , Sharp, Richard R. , Spector‐Bagdady, Kayte , Wang, Na , Roberts, J. Scott , Group, for the PGen Study, Roberts, J. Scott , Lehmann, Lisa Soleymani , Green, Robert C. , Group, for the PGen Study, Sharp, Richard R , Gray, Stacy W

Mayo Clinic

The Milbank Quarterly | June 7, 2017 | Volume: 95 | Issue: 2 | Pages: 291-318

10.1111/1468-0009.12262 | PMID 28589610 Get It

Policy Points: The policy context of direct‐to‐consumer personal genomic testing (DTC‐PGT) has been evolving over the last decade, with little empirical data available about consumers’ perspectives. A majority of consumers of DTC‐PGT supported expanded access to services and their integration into the medical context and opposed more governmental regulation. Consumers’ attitudes about access to services and regulation did not vary based on the specific genetic risk information they received from companies, but may vary based on whether consumers perceived their DTC experience negatively. ContextWhile policymakers have been considering the appropriateness of direct‐to‐consumer personal genomic testing (DTC‐PGT) for more than a decade, there is little empirical data on consumers’ views regarding the regulation of these products. No research has assessed whether consumers’ personal experience with testing is related to their views about access to and regulation of DTC tests.MethodsData were analyzed from the PGen Study, a longitudinal prospective cohort of DTC‐PGT customers of 23andMe (n = 564) and Pathway Genomics (n = 377; total N = 941). Consumers were sent an electronic survey before receiving genetic test results and again 6 months after receipt of results.FindingsAt the 6‐month follow‐up, more than 80% of participants believed that people have a right to access genetic information directly, that parents should be able to get DTC‐PGT testing for their children, and that genetic information should be kept private. Participants supported health insurance coverage of PGT (60%), wider availability of PGT (68%), and inclusion of genetic information in medical records (63%). Participants were less supportive of government regulation (28%) and restricting testing to clinical settings (14%). Conservative political ideology was associated with less support for government regulation (P < 0.001), as was feeling more confident in one's genetic knowledge (P < 0.05). Participants’ level of computed genetic risk for common diseases, as indicated by their actual test results received from companies, showed no relationship with attitudes. However, those who perceived that they had received elevated risk results expressed lower support for expanded availability and incorporation of PGT into health care (P < 0.01). Those who reported being upset by their genetic test results were less likely to endorse access to DTC products without a medical professional (P < 0.01).ConclusionsPGT consumers supported expanded access to these services and opposed additional regulation. Users who had a negative personal experience with PGT testing were less supportive of expanded availability without a medical professional.
Pregnant patients' risk perception of prenatal test results with uncertain fetal clinical significance: ultrasound versus advanced genetic testing
Richards, Elliott G. , Sangi‐Haghpeykar, Haleh , Veyver, Ignatia B. Van den , Fruhman, Gary , McGuire, Amy L

Mayo Clinic

Prenatal Diagnosis | August 19, 2015 | Volume: 35 | Issue: 12 | Pages: 1213-1217

10.1002/pd.4680 | PMID 26287960 Get It

AbstractObjectiveA common concern of utilizing prenatal advanced genetic testing is that a result of uncertain clinical significance will increase patient anxiety. However, prenatal ultrasound may also yield findings of uncertain significance, such as ‘soft markers’ for fetal aneuploidy, or findings with variable prognosis, such as mild ventriculomegaly. In this study we compared risk perception following uncertain test results from each modality.MethodsA single survey with repeated measures design was administered to 133 pregnant women. It included ‘intolerance of uncertainty’ questions, two hypothetical scenarios involving prenatal ultrasound or advanced genetic testing, and response questions. The primary outcome was risk perception score.ResultsRisk perception did not vary significantly between ultrasound and genetic scenarios (p = 0.17). The genetic scenario scored a higher accuracy (p = 0.04) but lower sense of empowerment (p = 0.01). Furthermore, patients were more likely to seek additional testing after an ultrasound than after genetic testing (p = 0.05). There were no differences in other secondary outcomes including perception of life‐altering consequences and hypothetical worry, anxiety, confusion, or medical care decisions.ConclusionsOur data suggest that uncertain findings on prenatal genetic testing do not elicit a higher perception of risk or anxiety when compared to ultrasound findings of comparable uncertainty. © 2015 John Wiley & Sons, Ltd.